.Pharmacolibrary.Drugs.ATC.L.L01XH02 .Pharmacolibrary.Drugs.ATC.L.L01XH02| name: | Romidepsin |
| ATC code: | L01XH02 | route: | intravenous |
| n-compartments | 2 |
Romidepsin is a cyclic peptide histone deacetylase (HDAC) inhibitor used primarily for the treatment of cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). It is approved by regulatory agencies such as the FDA for these indications.
Pharmacokinetic parameters are reported in adult patients with advanced cancers, administered intravenous infusion over 4 hours. Parameters derived from population PK modeling.
Peer, CJ, et al., & Figg, WD (2018). A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. Cancer chemotherapy and pharmacology 82(3) 565–570. DOI:10.1007/s00280-018-3631-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29951694
Gerber, DE, et al., & Schiller, JH (2015). Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 90(3) 534–541. DOI:10.1016/j.lungcan.2015.10.008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26474959
Stadler, WM, et al., & Thompson, JA (2006). A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clinical genitourinary cancer 5(1) 57–60. DOI:10.3816/CGC.2006.n.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16859580